PDCD1 and non-small cell lung carcinoma: Like NSCLC, anti-PD-1/PD-L1 combination therapy correlated with prolonged overall survival of these patients regardless of PD-L1 expression (HR for PD-L1 <1% vs. ≥1% [0.67 vs. 0.55], <5% vs. ≥5% [0.52 vs. 0.62], < 10% vs. ≥10% [0.58 vs. 0.51]; all P < 0.05, Figure 3(b)).